# Megestrol

## Megatus 40mg/mL 120mL suspension

| 藥物代碼 | LMEG4 |
| :--- | :--- |
| 適應症 | Treatment of anorexia, cachexia, or unexplained significant weight loss in patients with AIDS or cancer. Palliative treatment of breast and endometrial carcinoma. |
| 副作用 | Abdominal pain, chest pain, infections. Cardiomyopathy, palpitations. Constipation, dry mouth, liver enlargement, increased salivation, oral candida infections. Leukopenia, increased LDH, edema. CNS disturbances. Dysnea, cough, pharyngitis, lung disease. Hair loss, papule, pruritus & other skin disorders, poor vision, proteinuria, incontinence, UTI, gynecomastia.Cardiovascular: Hypertension \(?8%\), cardiomyopathy \(1% to 3%\), chest pain \(1% to 3%\), edema \(1% to 3%\), palpitation \(1% to 3%\), peripheral edema \(1% to 3%\), heart failure Central nervous system: Headache \(?10%\), insomnia \(?6%\), fever \(1% to 6%\), pain \(?6%, similar to placebo\), abnormal thinking \(1% to 3%\), confusion \(1% to 3%\), depression \(1% to 3%\), hypoesthesia \(1% to 3%\), seizure \(1% to 3%\), mood changes, malaise, lethargy Dermatologic: Rash \(2% to 12%\), alopecia \(1% to 3%\), pruritus \(1% to 3%\), vesiculobullous rash \(1% to 3%\) Endocrine & metabolic: Hyperglycemia \(?6%\), gynecomastia \(1% to 3%\), adrenal insufficiency, amenorrhea, breakthrough bleeding, cervical erosion and secretions \(changes\), breast tenderness increased, Cushing's syndrome, diabetes, glucose intolerance, HPA axis suppression, hot flashes, hypercalcemia, menstrual flow changes, spotting, vaginal bleeding pattern changesGastrointestinal: Diarrhea \(6% to 15%, similar to placebo\), flatulence \(?10%\), vomiting \(?6%\), nausea \(?5%\), dyspepsia \(?4%\), abdominal pain \(1% to 3%\), constipation \(1% to 3%\), salivation increased \(1% to 3%\), xerostomia \(1% to 3%\), weight gain \(not attributed to edema or fluid retention\)Genitourinary: Impotence \(4% to 14%\), decreased libido \(?5%\), urinary incontinence \(1% to 3%\), urinary tract infection \(1% to 3%\), urinary frequency \(?2%\)Hematologic: Anemia \(?5%\), leukopenia \(1% to 3%\)Hepatic: Hepatomegaly \(1% to 3%\), LDH increased \(1% to 3%\), cholestatic jaundice, hepatotoxicityNeuromuscular & skeletal: Weakness \(2% to 6%\), neuropathy \(1% to 3%\), paresthesia \(1% to 3%\), carpal tunnel syndrome Ocular: Amblyopia \(1% to 3%\)Renal: Albuminuria \(1% to 3%\)Respiratory: Dyspnea \(1% to 3%\), cough \(1% to 3%\), pharyngitis \(1% to 3%\), pneumonia \(?2%\), hyperpnea Miscellaneous: Diaphoresis \(1% to 3%\), herpes infection \(1% to 3%\), infection \(1% to 3%\), moniliasis \(1% to 3%\), tumor flare Postmarketing and/or case reports: Thromboembolic phenomena \(including deep vein thrombosis, pulmonary embolism, thrombophlebitis\) |
| 禁忌 | 1.Hypersensitivity to megestrol or any component of the formulation. 2.Known or suspected pregnancy. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Cachexia associated with AIDS or cancer: \(initial\) 40 mg/mL oral suspension, 400 \(10 mL\) or 800 mg \(20 mL\) daily Cachexia associated with AIDS or cancer: \(maintenance\) daily doses of 400 and 800 mg/day of megestrol acetate oral suspension were found to be clinically effective Carcinoma of prostate, Advanced hormone-refractory: 120 mg \(93.8 mg/square meter of body surface area\) as a single daily dose in combination with a 0.1 mg diethylstilbestrol tablet Endometrial carcinoma, palliative treatment of advanced disease \(recurrent, inoperable, or metastatic\): 40-320 mg/day in divided doses Breast cancer, palliative treatment of advanced disease \(recurrent, inoperable, or metastatic\): 40 mg 4 times daily |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | N/A |
| 附帶說明 | Use is contraindicated for the treatment of anorexia or cachexia in pregnant females with HIV infection. Megestrol may cause fetal harm if administered during pregnancy.\(UpToDate\)2021/0125 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | Due to the potential for adverse reaction in the breastfed newborn, the manufacturer recommends  discontinuing breastfeeding while receiving megestrol for the treatment of cancer. Due to the potential for HIV transmission, breastfeeding is not recommended when treating females for anorexia or cachexia associated with HIV infection. \(UpToDate\)2021/0125 |
| 注射劑給藥建議途徑 | AC, AC15, PC, PO, WM |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

